Previous 10 | Next 10 |
Gainers: [[AKBA]] +12.1%. [[SYBX]] +7.1%. [[ARDX]] +5.2%. [[ODT]] +4.9%. [[BYND]] +4.2%.Losers: [[FGEN]] -29.2%. [[FIXX]] -10.2%. [[MAXN]] -6.8%. [[IONS]] -5.8%. [[OM]] -5.4%. For further details see: AKBA, SYBX, FGEN and FIXX among after-hours movers
Homology Medicines (FIXX) announces that the company intends to offer and sell $50M of shares in an underwritten public offering.Expects to grant the underwriter a 30-day option to purchase up to an additional $7.5M shares.Intends to use the net proceeds from the offering, in addition to...
- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End - - On Track to Initiate Phase 1/2 Trials With In Vivo Gene Editing Candidate for PKU and Gene Therapy Candidate for Hunter Syndrome This Year - - Plans to Name a New De...
- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication - BEDFORD, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today it has re...
BEDFORD, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences: Cowen 41 st Annual Health Care Conference Panel discussion: March 1 at 1...
- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - - Data at WORLD Symposium ™ Support Plans to Initiate a HMI-203 Phase 1/2 Clinical Trial This Year - BEDF...
Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%. For further details see: AY, ABUS, ACLS and FIXX among after-hours movers
Homology Medicines ([[FIXX]] +4.3%) has outlined plans to initiate two additional Phase 1/2 dose-escalation trials in 2021 with its gene therapy candidate for Hunter syndrome and gene editing candidate, which is for Phenylketonuria ((PKU)).Additionally, the company plans to nam...
- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients - - Company Plans to Nominate Additional Development Candidate in New Therapeutic Area - - Management Highlights Anticipated 2021 Milestones...
Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102), 3-IND-enabling phase therapeutics, and 3 in the early research phase on top of t...
News, Short Squeeze, Breakout and More Instantly...
Homology Medicines Inc. Company Name:
FIXX Stock Symbol:
NASDAQ Market:
Homology Medicines Inc. Website:
2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...